PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00417885
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
- Conditions
- Pain
- Interventions
- Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 467
- Registration Number
- NCT00415597
- Locations
- 🇺🇸
Stephen Miller, MD, Las Vegas, Nevada, United States
🇺🇸Steven Siwek, MD, Phoenix, Arizona, United States
🇺🇸Michael Loes, MD, Phoenix, Arizona, United States
Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2013-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 162
- Registration Number
- NCT00414661
- Locations
- 🇺🇦
Pfizer Investigational Site, Vinnitsa, Ukraine
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4488
- Registration Number
- NCT00413699
- Locations
- 🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸Rheumatology Associates, Portland, Maine, United States
🇮🇳Arthritis Research and Care Foundation Centre for Rheumatic Diseases, Pune, Maharashtra, India
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 509
- Registration Number
- NCT00413660
- Locations
- 🇹🇷
Pfizer Investigational Site, Izmir, Turkey
Study Evaluating the Effects of IMA-638 on Allergen-Induced Airway Responses in Subjects With Mild Atopic Asthma
- Conditions
- Asthma
- Interventions
- Biological: IMA-638 is a biologic
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00410280
- Locations
- 🇨🇦
McMaster University Medical, Hamilton, Ontario, Canada
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦Hopital Laval, Ste-Foy, Quebec, Canada
Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT00409175
- Locations
- 🇵🇹
Unidade Clinica de Paramiloidose-Hospital Santo Antonio, Porto, Norte, Portugal
🇺🇸MGH Neuropathy Laboratory, Boston, Massachusetts, United States
🇦🇷FLENI-Hepatology and Organ Transplant Dept., Ciudad de Buenos Aires, Buenos Aires Province, Argentina
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2010-11-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT00408954
- Locations
- 🇸🇰
Pfizer Investigational Site, Trencin, Slovakia
Study for Evaluating Different Methods of Measuring Depression Treatment Response
- Conditions
- Depressive Disorder, Major
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 165
- Registration Number
- NCT00406952
- Locations
- 🇺🇸
Pfizer Investigational Site, Midvale, Utah, United States
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 83
- Registration Number
- NCT00404495
- Locations
- 🇬🇧
Pfizer Investigational Site, Sutton, United Kingdom